Literature DB >> 21210012

Contrast enhanced ultrasound in focal liver lesions--a cost efficiency study.

Roxana Sirli1, Ioan Sporea, Alina Martie, Alina Popescu, Mirela Dănilă.   

Abstract

UNLABELLED: Contrast enhanced ultrasound (CEUS) has a well established role for the evaluation of focal liver lesions (FLL). The AIM of our paper was to evaluate if CEUS is a cost-efficient method for the first line evaluation of FLL. MATERIAL AND
METHOD: We performed a prospective study that included all the CEUS evaluations performed in our Department during a 6 months period (September 2009-March 2010). CEUS evaluation was performed with a Siemens Acuson S2000TM Ultrasound System following an intravenous bolus injection of 2.4 ml SonoVue(R) (Bracco). A CEUS examination was considered conclusive if, following contrast, the FLL had a typical enhancement pattern(after EFSUMB Guidelines 2008), allowing its classification as hemangioma, FNH, adenoma, hepatocellular carcinoma, metastasis, fatty-free area, focal fatty infiltration. We compared the costs of a CEUS positive diagnosis, to the cost of contrast CT and/or contrast MRI positive diagnosis. We also included the additional costs of CT and/or MRI, if CEUS was not conclusive. The cost of CEUS was calculated as the cost of 1/2 vial of SonoVue + the cost of abdominal ultrasound (150 + 30 = 180 RON). The costs of contrast CT scan and MRI were 285 and 650 RON respectively (mean costs practiced in Timisoara).
RESULTS: In our study were included 316 FLL: 163 (51.6 %) in patients without hepatitis and 153 (48.4 %) in patients with chronic hepatopathies (in 133 cases liver cirrhosis and in 20 cases chronic hepatitis). CEUS was conclusive in 250 (79.1%) of the 316 cases, the cost for the evaluation of these patients being 45,000 RON. For the other 66 patients, the diagnosis cost will include the cost of CEUS + the cost of contrast CT: 30,690 RON. If contrast MRI was used for the differential diagnosis, the cost would be 54,780 RON. So the total cost of diagnosing 316 FLL would be 75,690 RON or 99,780 RON. If contrast CT would be used as the first line diagnosis for the 316 FLL, the cost would be 90,060 RON, by CEUS saving 14,370 RON, or 45.5 RON/lesion (using contrast CT for the differential diagnosis). If contrast MRI would be used as the first line diagnosis, the cost would be 205,400 RON, by CEUS saving 105,620 RON, or 334.2 RON/lesion (using contrast MRI for the differential diagnosis).
CONCLUSION: CEUS is a cost-efficient method as a first line diagnosis of FLL as compared to first line contrast-CT or first-line MRI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21210012

Source DB:  PubMed          Journal:  Med Ultrason        ISSN: 1844-4172            Impact factor:   1.611


  13 in total

1.  Contrast- and non-contrast-enhanced ultrasonography (US) findings of hepatic metastasis from malignant pheochromocytoma/paraganglioma.

Authors:  Sachiko Nakano; Yoshito Tsushima; Tetsuya Higuchi; Ayako Taketomi-Takahashi; Makoto Amanuma
Journal:  Jpn J Radiol       Date:  2012-01-24       Impact factor: 2.374

2.  How often hepatocellular carcinoma has a typical pattern in contrast enhanced ultrasound?

Authors:  Alina Martie; Ioan Sporea; Roxana Sirli; Alina Popescu; Mirela Danila
Journal:  Maedica (Buchar)       Date:  2012-09

Review 3.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

Review 4.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

5.  Contrast-enhanced ultrasound of the kidney: a single-institution experience.

Authors:  Sheng F Oon; Robert W Foley; Deirdre Quinn; David M Quinlan; Robert G Gibney
Journal:  Ir J Med Sci       Date:  2017-12-07       Impact factor: 1.568

6.  Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study.

Authors:  Ilario de Sio; Maddalena D Iadevaia; Luigi M Vitale; Marco Niosi; Anna Del Prete; Chiara de Sio; Lorenzo Romano; Annalisa Funaro; Rosaria Meucci; Alessandro Federico; Carmelina Loguercio; Marco Romano
Journal:  United European Gastroenterol J       Date:  2014-08       Impact factor: 4.623

7.  Contrast enhancement ultrasound application in focal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey).

Authors:  Mirko D'Onofrio; Laura Romanini; Carla Serra; Fabrizio Magnolfi; Michele Bertolotto; Emilio Quaia; Gino Puntel; Alessandro Colleoni; Erica Fiorini; Cristina Cenci; Elena Santi; Valentina Ciaravino; Francesco Laffranchi; Orlando Catalano; Vito Cantisani; Fabrizio Calliada; Lorenzo Derchi
Journal:  J Ultrasound       Date:  2015-11-02

8.  Activity-based cost analysis of contrast-enhanced ultrasonography (CEUS) related to the diagnostic impact in focal liver lesion characterisation.

Authors:  Arianna Lorusso; Emilio Quaia; Gabriele Poillucci; Fulvio Stacul; Guido Grisi; Maria Assunta Cova
Journal:  Insights Imaging       Date:  2015-05-09

Review 9.  REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE.

Authors:  Olena Mandrik; Saskia Knies; Zoltan Kalo; Johan L Severens
Journal:  Int J Technol Assess Health Care       Date:  2015       Impact factor: 2.188

10.  Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging.

Authors:  Sung Woo Ryu; Gene Hyun Bok; Jae Young Jang; Soung Won Jeong; Nam Seok Ham; Ji Hye Kim; Eui Ju Park; Jin Nyoung Kim; Woong Cheul Lee; Kwang Yeun Shim; Sae Hwan Lee; Sang Gyune Kim; Sang Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.